Microneedle-integrated biosensor detects drugs in interstitial fluid, implying potential for portable health monitoring.
We present a microneedle-integrated wearable biosensor array for minimally invasive detection of heroin, cocaine, and methamphetamine in interstitial fluid (ISF). The platform leverages aptamer-functionalized cholesteric liquid crystal-based interpenetrating polymer networks (CLCN-IPNs), which generate colorimetric responses through photonic bandgap (λPBG) shifts upon target binding. Each sensor chip exhibits a distinct initial color, allowing for multiplexed drug detection via visible spectral shifts. The biosensor array is embedded in a flexible polydimethylsiloxane (PDMS) patch interfaced with a microneedle substrate for minimally invasive ISF sampling. Upon drug exposure, the CLCN-IPN hydrogel contracts, inducing a blue shift in λPBG. The device demonstrated high selectivity and sensitivity, with detection limits below 1.3 ng/mL for all drugs. In vitro validation using a chicken tissue model confirmed accurate drug recovery (92.5-115%) and strong visual output. This battery-free, portable, and low-cost device offers a promising step toward next-generation wearable diagnostics for drug detection in clinical, forensic, and personal health applications.
No takes yet. Share an insight, caveat, or question.
Bashir et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: